Pharmaceutical Patent Extensions Upended: What Otsuka v Sun Pharma Means for Your Business

If you're in the pharmaceutical industry in Australia, you need to pay attention to a decision that has the potential to shake up the entire patent term extension (PTE) system.

In late 2025, the Full Federal Court handed down a ruling in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161 that:

Overturned nearly 20 years of legal precedent
Potentially invalidated many existing patent extensions
Paused all new PTE applications at IP Australia
Set the stage for a High Court appeal that could reshape the industry

Let's break down what happened, why it matters, and what pharmaceutical businesses need to do right now.

What Are Pharmaceutical Patent Term Extensions?

First, a quick refresher for those outside the pharma world.

Developing a new drug is expensive and time-consuming. It typically takes 10 to 15 years from initial research to a drug reaching patients. During this time, the clock is ticking on the patent that protects the drug.

By the time a drug is approved and reaches the market, much of the patent's 20-year life may already be gone. This means competitors could launch generic versions while the innovator company is still trying to recoup its investment.

Patent term extensions (PTEs) solve this problem. They allow pharmaceutical companies to extend their patent term by up to 5 years to compensate for the time lost during regulatory approval.

It's a balance: encourage innovation in drug development while eventually allowing cheaper generic alternatives to reach the market.

How It Worked Before (For 20 Years)

Here's where things get interesting. For almost two decades, Australian courts and IP Australia operated on the assumption that patent term extensions could be granted for drug formulations.

What's a formulation? It's the complete medicine as you'd take it — the active ingredient (the drug itself) plus any other components like binders, coatings, or release mechanisms.

For example, if the active ingredient is "aripiprazole" (used to treat schizophrenia and bipolar disorder), a "controlled-release formulation" might be aripiprazole combined with special coatings that slowly release the drug into your body over time.

Under the old approach, both the pure active ingredient and formulations of it could qualify for PTEs. This made sense from a policy perspective: the formulation is what patients actually take, and it still took years to get approved.

What the Otsuka v Sun Pharma Decision Changed

Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161 involved Otsuka Pharmaceutical holding a patent for a controlled-release formulation of aripiprazole. They applied for and received a PTE — exactly as the law had been understood for 20 years.

Then Sun Pharma ANZ Pty Ltd (a generic drug manufacturer) challenged that extension. They argued: "A formulation is not a 'pharmaceutical substance.' Only the active ingredient itself qualifies."

The Full Federal Court agreed with Sun Pharma ANZ Pty Ltd — and in doing so, they unanimously overturned nearly two decades of authority.

The Court's Reasoning

The Court looked at the definition of "pharmaceutical substance" in the Patents Act and concluded:

A "substance" must be something physical and tangible
It must be "active" — meaning capable of interacting with the human body
Only the active pharmaceutical ingredient (API) meets this definition
Excipients, coatings, and other formulation components are not "active"
Therefore, formulations do not qualify for PTEs

The Immediate Impact

IP Australia paused all PTE applications while it considers the decision
Many existing PTEs are now vulnerable to challenge and revocation
Generic manufacturers may now have grounds to challenge PTEs they previously couldn't touch
Otsuka Pharmaceutical Co Ltd has sought special leave to appeal to the High Court

What This Means for Pharmaceutical Companies

1. Review Your Portfolio Immediately

If you're a pharmaceutical company operating in Australia, this should be your number one priority:

Identify every PTE you hold
Determine which are based on formulations vs. pure APIs
Assess the commercial impact of losing each PTE (up to 5 years of exclusivity per drug)
Estimate the revenue impact of generic competition entering earlier than expected

2. Prepare for Challenges

Generic manufacturers may now challenge PTEs that were previously considered secure. Be prepared for:

Opposition proceedings
Court challenges
Urgent applications to revoke PTEs
Strategic decisions about which PTEs to defend and which to let go

3. Adjust Your Patent Strategy

Going forward, if PTEs are only available for pure APIs:

Focus your patent portfolio on API patents if PTEs are important to your business model
Consider formulation patents for other forms of protection (copyright, trade secrets, regulatory data protection)
File earlier to maximise the remaining patent term
Evaluate whether formulation innovations are still worth pursuing without PTE protection

4. Consider Legislative Reform

The Full Federal Court's decision was based on statutory interpretation — what the existing law means, not what it should mean. If the government and industry believe the law should be changed to allow formulation PTEs, that's a matter for Parliament, not the courts.

The pharmaceutical industry may need to lobby for legislative reform to restore the previous position. This is a common pattern in IP law: courts interpret the law, but Parliament can change it.

What This Means for Generic Manufacturers

1. New Opportunities

If you're a generic drug manufacturer, this decision opens new avenues:

Challenge existing PTEs for formulations that were previously secure
Accelerate your product launch timelines if PTEs are invalidated
Review your competitive landscape — drugs you thought were protected for longer may now face earlier generic entry

2. Strategic Considerations

Monitor the High Court appeal — if Otsuka wins, the status quo is restored
Assess the cost-benefit of challenging PTEs (legal costs vs. market share gains)
Consider the regulatory implications — even without a PTE, regulatory data protection may still apply

What This Means for Patients and the Healthcare System

On one hand, if PTEs are invalidated, generic drugs could reach the Australian market sooner, potentially lowering costs for patients and the PBS (Pharmaceutical Benefits Scheme).

On the other hand, if innovator companies can't recover their R&D investment through PTEs, they may be less willing to invest in new drug development for the Australian market.

This is the fundamental tension in pharmaceutical patent policy: balancing innovation incentives with affordable access to medicines.

The High Court Appeal: What to Watch

Otsuka Pharmaceutical Co Ltd has applied for special leave to appeal to the High Court. Here's what to watch for:

If the High Court Upholds the Full Federal Court's ruling in Otsuka v Sun Pharma

The new test (APIs only) becomes permanent law
A wave of PTE challenges is likely
IP Australia will need to issue updated guidance
The industry may push for legislative reform

If the High Court Reverses

The 20-year line of authority is restored
Existing PTEs remain secure
IP Australia resumes processing applications
The status quo is preserved

If the High Court Delays or Refuses Leave

The Full Federal Court's decision stands as the law
Uncertainty continues
Businesses must plan for the worst-case scenario

Practical Steps for Pharma Businesses Right Now

Immediate Actions (This Week)

Compile a list of all Australian PTEs you hold or are aware of
Categorise each PTE as API-based or formulation-based
Quantify the commercial impact of each PTE being invalidated
Brief your legal team on the decision and its implications

Short-term Actions (This Month)

Review pending PTE applications and assess their vulnerability
Evaluate potential challenges from generic competitors
Consider filing for special leave if you hold vulnerable PTEs
Engage with industry bodies on potential legislative reform

Medium-term Actions (This Quarter)

Adjust your patent filing strategy based on the new landscape
Review licensing agreements that reference PTEs
Update investor communications if PTEs are material to your valuation
Monitor High Court proceedings and adjust strategy accordingly

The Bottom Line

The Otsuka v Sun Pharma decision is one of the most significant pharmaceutical IP developments in Australia in decades. Whether it ultimately stands or is reversed, it has created immediate uncertainty that pharmaceutical businesses cannot ignore.

If you're in the pharma industry in Australia, you need to act now. Review your portfolio, assess your exposure, and prepare for whatever outcome the High Court delivers.

The next 12 months will be critical for the future of pharmaceutical patent protection in Australia.

This article is for general information only and does not constitute legal advice. If you have questions about pharmaceutical patent term extensions in Australia, consult a qualified patent attorney specialising in pharmaceutical IP.